References
- American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders. 5th ed. https://doi.org/https://doi.org/10.1176/appi.books.9780890425596
- Andrilla, C. H. A., Moore, T. E., Patterson, D. G., & Larson, E. H. (2019). Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. The Journal of Rural Health: Official Journal of the American Rural Health Association and the National Rural Health Care Association, 35(1), 108–112. https://doi.org/https://doi.org/10.1111/jrh.12307
- Barbieri, V. A., Mishlen, K., Sullivan, M., & Bisaga, A. (2017). Baseline predictors of outpatient induction onto extended-release naltrexone. Drug and Alcohol Dependence, 171, e15. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2016.08.056
- Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015). Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes. Journal of Substance Abuse Treatment, 52, 48–57. https://doi.org/https://doi.org/10.1016/j.jsat.2014.12.011
- Bhalla, I. P., Stefanovics, E. A., & Rosenheck, R. A. (2017). Clinical epidemiology of single versus multiple substance use disorders: Polysubstance use disorder. Medical Care, 55(Suppl 9), S24–S32. https://doi.org/https://doi.org/10.1097/MLR.0000000000000731
- Bukten, A., Skurtveit, S., Waal, H., & Clausen, T. (2014). Factors associated with dropout among patients in opioid maintenance treatment (OMT) and predictors of re-entry. A national registry-based study. Addictive Behaviors, 39(10), 1504–1509. https://doi.org/https://doi.org/10.1016/j.addbeh.2014.05.007
- Burns, L., Randall, D., Hall, W. D., Law, M., Butler, T., Bell, J., & Degenhardt, L. (2009). Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: Patient characteristics and patterns and predictors of treatment retention. Addiction (Abingdon, England), 104(8), 1363–1372. https://doi.org/https://doi.org/10.1111/j.1360-0443.2009.02633.x
- Carlson, R. G., Daniulaityte, R., Silverstein, S. M., Nahhas, R. W., & Martins, S. S. (2020). Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose? International Journal of Drug Policy79(May), 102722. https://doi.org/https://doi.org/10.1016/j.drugpo.2020.102722
- Carroll, J. J., Marshall, B. D. L., Rich, J. D., & Green, T. C. (2017). Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study. The International Journal on Drug Policy, 46, 136–145. https://doi.org/https://doi.org/10.1016/j.drugpo.2017.05.023
- Cicero, T. J., Ellis, M. S., & Kasper, Z. A. (2020). Polysubstance use: A broader understanding of substance use during the opioid crisis. American Journal of Public Health, 110(2), 244–250. https://doi.org/https://doi.org/10.2105/AJPH.2019.305412
- Daniulaityte, R., Juhascik, M. P., Strayer, K. E., Sizemore, I. E., Zatreh, M., Nahhas, R. W., Harshbarger, K. E., Antonides, H. M., Martins, S. S., & Carlson, R. G. (2019). Trends in fentanyl and fentanyl analogue-related overdose deaths – Montgomery County, Ohio, 2015–2017. Drug and Alcohol Dependence, 198, 116–120.
- Daniulaityte, R., Silverstein, S. M., Crawford, T. N., Martins, S. S., Zule, W., Zaragoza, A. J., & Carlson, R. G. (2020). Methamphetamine use and its correlates among individuals with opioid use disorder in a Midwestern U.S. City. Substance Use & Misuse, 55(11), 1781–1789. https://doi.org/https://doi.org/10.1080/10826084.2020.1765805
- Drug Testing Supplies | American Screening. 2021. [WWW Document]. Retrieve August 1, 2021, from https://www.americanscreeningcorp.com/pc_product_detail.asp?key=2A8F0D0A34284C60BB51A3907ABEBB17.
- Ellis, M. S., Kasper, Z. A., & Cicero, T. J. (2018). Twin epidemics: The surging rise of methamphetamine use in chronic opioid users. Drug and Alcohol Dependence, 193, 14–20. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2018.08.029
- Fareed, A., Vayalapalli, S., Casarella, J., & Drexler, K. (2012). Effect of buprenorphine dose on treatment outcome. Journal of Addictive Diseases, 31(1), 8–18. https://doi.org/https://doi.org/10.1080/10550887.2011.642758
- Friedrichs, A., Spies, M., Härter, M., & Buchholz, A. (2016). Patient preferences and shared decision making in the treatment of substance use disorders: A systematic review of the literature. PLoS One, 11(1), e0145817. https://doi.org/https://doi.org/10.1371/journal.pone.0145817
- Gerra, G., Borella, F., Zaimovic, A., Moi, G., Bussandri, M., Bubici, C., & Bertacca, S. (2004). Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug and Alcohol Dependence, 75(1), 37–45. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2003.11.017
- Gibson, A., Degenhardt, L., Mattick, R. P., Ali, R., White, J., & O’Brien, S. (2008). Exposure to opioid maintenance treatment reduces long-term mortality. Addiction (Abingdon, England), 103(3), 462–468. https://doi.org/https://doi.org/10.1111/j.1360-0443.2007.02090.x
- Gladden, R. M., O’Donnell, J., Mattson, C. L., & Seth, P. (2019). Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine - 25 states, July-December 2017 to January-June 2018. MMWR. Morbidity and Mortality Weekly Report, 68(34), 737–744. https://doi.org/https://doi.org/10.15585/mmwr.mm6834a2
- Harrell, F. E. (2015). Regression modeling strategies: With applications to linear models, logistic and ordinal regression, and survival analysis. 2nd ed. Springer series in statistics.
- Hedges, D. M., Obray, J. D., Yorgason, J. T., Jang, E. Y., Weerasekara, V. K., Uys, J. D., Bellinger, F. P., & Steffensen, S. C. (2018). Methamphetamine induces dopamine release in the nucleus accumbens through a sigma receptor-mediated pathway. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 43(6), 1405–1414. https://doi.org/https://doi.org/10.1038/npp.2017.291
- Hser, Y.-I., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., Cohen, A., & Ling, W. (2014). Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction, 109(1), 79–87. https://doi.org/https://doi.org/10.1111/add.12333
- Hulse, G. K., Morris, N., Arnold-Reed, D., & Tait, R. J. (2009). Improving clinical outcomes in treating heroin dependence: Randomized, controlled trial of oral or implant naltrexone. Archives of General Psychiatry, 66(10), 1108–1115. https://doi.org/https://doi.org/10.1001/archgenpsychiatry.2009.130
- Jones, C. M., Underwood, N., & Compton, W. M. (2020). Increases in methamphetamine use among heroin treatment admissions in the United States, 2008–17. Addiction, 115(2), 347–353. https://doi.org/https://doi.org/10.1111/add.14812
- Kahn, L. S., Wozniak, M., Vest, B. M., & Moore, C. (2020). “Narcan encounters:” overdose and naloxone rescue experiences among people who use opioids. Substance Abuse. Advance online publication. https://doi.org/https://doi.org/10.1080/08897077.2020.1748165
- Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011). Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. The Lancet, 377(9776), 1506–1513. https://doi.org/https://doi.org/10.1016/S0140-6736(11)60358-9
- Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine, 169(3), 137–145. https://doi.org/https://doi.org/10.7326/M17-3107
- LaRue, L., Twillman, R. K., Dawson, E., Whitley, P., Frasco, M. A., Huskey, A., & Guevara, M. G. (2019). Rate of Fentanyl Positivity Among Urine Drug Test Results Positive for Cocaine or Methamphetamine. JAMA Network Open, 2(4), e192851. https://doi.org/https://doi.org/10.1001/jamanetworkopen.2019.2851
- Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., King, J., Lindblad, R., Liu, D., Matthews, A. G., May, J., Peavy, K. M., Ross, S., Salazar, D., Schkolnik, P., … Rotrosen, J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. The Lancet , 391(10118), 309–318. https://doi.org/https://doi.org/10.1016/S0140-6736(17)32812-X
- Lin, L. A., Bohnert, A. S. B., Blow, F. C., Gordon, A. J., Ignacio, R. V., Kim, H. M., & Ilgen, M. A. (2021). Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Addiction (Abingdon, England), 116(1), 96–104. https://doi.org/https://doi.org/10.1111/add.15116
- Lopez, A. M., Dhatt, Z., Howe, M., Al-Nassir, M., Billing, A., Artigiani, E., & Wish, E. D. (2021). Co-use of methamphetamine and opioids among people in treatment in Oregon: A qualitative examination of interrelated structural, community, and individual-level factors. The International Journal on Drug Policy, 91, 103098. https://doi.org/https://doi.org/10.1016/j.drugpo.2020.103098
- Magura, S., Nwakeze, P. C., & Demsky, S. (1998). Pre- and in-treatment predictors of retention in methadone treatment using survival analysis . Addiction (Abingdon, England), 93(1), 51–60. https://doi.org/https://doi.org/10.1046/j.1360-0443.1998.931516.x
- Marcovitz, D. E., McHugh, R. K., Volpe, J., Votaw, V., & Connery, H. S. (2016). Predictors of early dropout in outpatient buprenorphine/naloxone treatment. The American Journal on Addictions, 25(6), 472–477. https://doi.org/https://doi.org/10.1111/ajad.12414
- Mars, S. G., Ondocsin, J., & Ciccarone, D. (2018). Sold as heroin: Perceptions and use of an evolving drug in Baltimore, MD. Journal of Psychoactive Drugs, 50(2), 167–176. https://doi.org/https://doi.org/10.1080/02791072.2017.1394508
- McElrath, K. (2018). Medication-assisted treatment for opioid addiction in the United States: Critique and commentary. Substance Use & Misuse, 53(2), 334–343. https://doi.org/https://doi.org/10.1080/10826084.2017.1342662
- Moeller, K. E., Kissack, J. C., Atayee, R. S., & Lee, K. C. (2017). Clinical interpretation of urine drug tests: What clinicians need to know about urine drug screens. Mayo Clinic Proceedings, 92(5), 774–796. https://doi.org/https://doi.org/10.1016/j.mayocp.2016.12.007
- Mogali, S., Khan, N. A., Drill, E. S., Pavlicova, M., Sullivan, M. A., Nunes, E., & Bisaga, A. (2015). Baseline characteristics of patients predicting suitability for rapid naltrexone induction. The American Journal on Addictions, 24(3), 258–264. https://doi.org/https://doi.org/10.1111/ajad.12180
- Morgan, J. R., Schackman, B. R., Leff, J. A., Linas, B. P., & Walley, A. Y. (2018). Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. Journal of Substance Abuse Treatment, 85, 90–96. https://doi.org/https://doi.org/10.1016/j.jsat.2017.07.001
- Noroozi, A., Malekinejad, M., & Rahimi-Movaghar, A. (2018). Factors influencing transition to shisheh (methamphetamine) among young people who use drugs in Tehran: A qualitative study. Journal of Psychoactive Drugs, 50(3), 214–223. https://doi.org/https://doi.org/10.1080/02791072.2018.1425808
- Nunes, E. V., Krupitsky, E., Ling, W., Zummo, J., Memisoglu, A., Silverman, B. L., & Gastfriend, D. R. (2015). Treating opioid dependence with injectable extended-release naltrexone (XR-NTX): Who will respond?Journal of Addiction Medicine, 9(3), 238–243. https://doi.org/https://doi.org/10.1097/ADM.0000000000000125
- Palmer, A., Scott, N., Dietze, P., & Higgs, P. (2020). Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: a qualitative study. Harm Reduction Journal, 17(1), 14–16. https://doi.org/https://doi.org/10.1186/s12954-020-00360-9
- Pardo, B., Taylor, J., Caulkins, J. P., Kilmer, B., Reuter, P., & Stein, B. D. (2019). The future of fentanyl and other synthetic opioids. RAND Corporation.
- Patrick, S. W., Fry, C. E., Jones, T. F., & Buntin, M. B. (2016). Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Affairs (Project Hope), 35(7), 1324–1332. https://doi.org/https://doi.org/10.1377/hlthaff.2015.1496
- Peiper, N. C., Clarke, S. D., Vincent, L. B., Ciccarone, D., Kral, A. H., & Zibbell, J. E. (2019). Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States. The International Journal on Drug Policy, 63, 122–128. https://doi.org/https://doi.org/10.1016/j.drugpo.2018.08.007
- R Core Team. (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing. https://www.R-project.org/
- Raby, W. N., Carpenter, K. M., Rothenberg, J., Brooks, A. C., Jiang, H., Sullivan, M., Bisaga, A., Comer, S., & Nunes, E. V. (2009). Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. The American Journal on Addictions, 18(4), 301–308. https://doi.org/https://doi.org/10.1080/10550490902927785
- Renner, J., Levounis, P., & LaRose, A. (2018). Office-based buprenorphine treatment of opioid use disorder. 2nd ed. American Psychiatric Association Publishing.
- Rossen, L. M., Bastian, B., Warner, M., & Khan, D. C. Y. (2000). Poisoning mortality in the United States: Comparison of national mortality statistics and poison control center reports. Annals of Emergency Medicine, 35, 440–448.
- Salehi, M., Emadossadat, A., Kheirabadi, G. R., Maracy, M. R., & Sharbafchi, M. R. (2015). The effect of buprenorphine on methamphetamine cravings. Journal of Clinical Psychopharmacology, 35(6), 724–727. https://doi.org/https://doi.org/10.1097/JCP.0000000000000408
- SAS Institute Inc. (2013). SAS/ACCESS® 9.4 Interface to ADABAS: Reference. SAS Institute Inc.
- Shearer, R. D., Howell, B. A., Bart, G., & Winkelman, T. N. A. (2020). Substance use patterns and health profiles among US adults who use opioids, methamphetamine, or both, 2015-2018. Drug and Alcohol Dependence, 214, 108162. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2020.108162
- Shulman, M., Wai, J. M., & Nunes, E. V. (2019). Buprenorphine treatment for opioid use disorder: an overview. CNS Drugs, 33(6), 567–580. https://doi.org/https://doi.org/10.1007/s40263-019-00637-z
- Sigmon, S. C., Bisaga, A., Nunes, E. V., O’Connor, P. G., Kosten, T., & Woody, G. (2012). Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. The American Journal of Drug and Alcohol Abuse, 38(3), 187–199. https://doi.org/https://doi.org/10.3109/00952990.2011.653426
- Silverstein, S. M., Daniulaityte, R., Getz, K., & Zule, W. (2021). "It’s crazy what meth can help you do": Lay beliefs, practices, and experiences of using methamphetamine to self-treat symptoms of opioid withdrawal . Substance Use & Misuse, 56 (11), 1687–1696. https://doi.org/https://doi.org/10.1080/10826084.2021.1949612
- Silverstein, S. M., Daniulaityte, R., Martins, S. S., Miller, S. C., & Carlson, R. G. (2019). "Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl. The International Journal on Drug Policy, 74, 76–83. https://doi.org/https://doi.org/10.1016/j.drugpo.2019.09.003
- Soyka, M., Zingg, C., Koller, G., & Kuefner, H. (2008). Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: Results from a randomized study. The International Journal of Neuropsychopharmacology, 11(5), 641–653. https://doi.org/https://doi.org/10.1017/S146114570700836X
- Strickland, J. C., Havens, J. R., & Stoops, W. W. (2019). A nationally representative analysis of “twin epidemics”: Rising rates of methamphetamine use among persons who use opioids. Drug and Alcohol Dependence, 204, 107592. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2019.107592
- Strickler, G. K., Zhang, K., Halpin, J. F., Bohnert, A. S. B., Baldwin, G. T., & Kreiner, P. W. (2019). Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing. Drug and Alcohol Dependence, 199, 1–9. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2019.02.010
- Sullivan, M. A., Bisaga, A., Pavlicova, M., Carpenter, K. M., Choi, C. J., Mishlen, K., Levin, F. R., Mariani, J. J., & Nunes, E. V. (2019). A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. The American Journal of Psychiatry, 176(2), 129–137. https://doi.org/https://doi.org/10.1176/appi.ajp.2018.17070732
- Tofighi, B., Williams, A. R., Chemi, C., Suhail-Sindhu, S., Dickson, V., & Lee, J. D. (2019). Patient barriers and facilitators to medications for opioid use disorder in primary care. Substance Use & Misuse, 54(14), 2409–2419. https://doi.org/https://doi.org/10.1080/10826084.2019.1653324
- Trujillo, K. A., Smith, M. L., & Guaderrama, M. M. (2011). Powerful behavioral interactions between methamphetamine and morphine. Pharmacology, Biochemistry, and Behavior, 99(3), 451–458. https://doi.org/https://doi.org/10.1016/j.pbb.2011.04.014
- Tsui, J. I., Mayfield, J., Speaker, E. C., Yakup, S., Ries, R., Funai, H., Leroux, B. G., & Merrill, J. O. (2020). Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. Journal of Substance Abuse Treatment, 109, 80–85. https://doi.org/https://doi.org/10.1016/j.jsat.2019.10.005
- Ward, J., Hall, W., & Mattick, R. P. (1999). Role of maintenance treatment in opioid dependence. The Lancet, 353(9148), 221–226. https://doi.org/https://doi.org/10.1016/S0140-6736(98)05356-2
- Weinstein, Z. M., Kim, H. W., Cheng, D. M., Quinn, E., Hui, D., Labelle, C. T., Drainoni, M. L., Bachman, S. S., & Samet, J. H. (2017). Long-term retention in Office Based Opioid Treatment with buprenorphine. Journal of Substance Abuse Treatment, 74, 65–70. https://doi.org/https://doi.org/10.1016/j.jsat.2016.12.010
- White, W., & White, I. M. (2016). Amphetamine and morphine may produce acute-withdrawal related hypoactivity by initially activating a common dopamine pathway. Physiology & Behavior, 165, 187–194. https://doi.org/https://doi.org/10.1016/j.physbeh.2016.07.015
- Williams, A. R., Nunes, E. V., Bisaga, A., Levin, F. R., & Olfson, M. (2019). Development of a cascade of care for responding to the opioid epidemic. The American Journal of Drug and Alcohol Abuse, 45(1), 1–10. https://doi.org/https://doi.org/10.1080/00952990.2018.1546862
- Wright, Q. E., Higginbotham, S., Bunk, E., & Covvey, J. R. (2020). The impact of a pharmacist-led naloxone education and community distribution project on local use of naloxone. Journal of the American Pharmacists Association: JAPhA, 60(3S), S56–S60. https://doi.org/https://doi.org/10.1016/j.japh.2019.11.027
- Yang, X., Wang, Y., Li, Q., Zhong, Y., Chen, L., Du, Y., He, J., Liao, L., Xiong, K., Yi, C. X., & Yan, J. (2018). The main molecular mechanisms underlying methamphetamine- induced neurotoxicity and implications for pharmacological treatment . Frontiers in Molecular Neuroscience, 11, 186. https://doi.org/https://doi.org/10.3389/fnmol.2018.00186
- Zweben, J. E., Cohen, J. B., Christian, D., Galloway, G. P., Salinardi, M., Parent, D., & Iguchi, M., Methamphetamine Treatment Project. (2004). Psychiatric symptoms in methamphetamine users. The American Journal on Addictions, 13(2), 181–190. https://doi.org/https://doi.org/10.1080/10550490490436055